BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
BCLI$1.14-7.3%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Condensed Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · March 31, · · December 31, | ||||||
| · · 2026 · · 2025 | ||||||
| · · Unaudited · · Audited | ||||||
| · · U.S. $ in thousands | ||||||
| ASSETS · · · · | ||||||
| | | | | | | |
| Current Assets: · · · · | ||||||
| Cash and cash equivalents | | $15 | | $29 | ||
| Other accounts receivable | | 122 | | 86 | ||
| Prepaid expenses and other current assets | | 47 | | 192 | ||
| Total current assets | | $184 | | $307 | ||
| | | | | | | |
| Long-Term Assets: | | | | | ||
| Prepaid expenses and other long-term assets | | $25 | | $25 | ||
| Restricted Cash | | | 191 | | | 247 |
| Right of use asset (Note 3) | | | 157 | | | 208 |
| Property and equipment, net | | 198 | | 235 | ||
| Total Long-Term Assets | | $571 | | $715 | ||
| | | | | | | |
| Total assets | | $755 | | $1,022 | ||
| | | | | | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | | | | | ||
| | | | | | | |
| Current Liabilities: | | | | | ||
| Accounts payable | | $7,317 | | $7,067 | ||
| Accrued expenses | | 414 | | 396 | ||
| Short-term loans (Note 6) | | | 1,329 | | | 967 |
| Operating lease liability (Note 3) | | | 159 | | | 208 |
| Employees related liability | | 2,545 | | 2,369 | ||
| Total current liabilities | | $11,764 | | $11,007 | ||
| | | | | | | |
| Total liabilities | | $11,764 | | $11,007 | ||
| | | | | | | |
| Stockholders’ Deficit: | | | | | ||
| Stock capital: (Note 4) | | 16 | | 16 | ||
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | | | | | | |
| Additional paid-in-capital | | 228,161 | | 227,058 | ||
| Treasury stock | | (116) | | (116) | ||
| Accumulated deficit | | (239,070) | | (236,943) | ||
| Total stockholders’ deficit | | $(11,009) | | $(9,985) | ||
| | | | | | | |
| Total liabilities and stockholders’ deficit | | $755 | | $1,022 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.